Lysimachia Capillipes Capilliposide Inhibits AKT Activation and Restores Sensitivity to Gefitinib in NSCLC with Acquired Gefitinib Resistance

被引：0
|
作者：
Zhang, Shirong [1 ]
Xu, Yasi [1 ]
Jin, Er [2 ]
Zhu, Lucheng [3 ]
Xia, Bing [4 ]
Chen, Xufeng
Ma, Shenglin [5 ,6 ]
机构：
[1] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Ctr Translat Med, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Resp Med, Hangzhou, Zhejiang, Peoples R China
[3] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Radiat Oncol, Nanjing, Jiangsu, Peoples R China
[4] Hangzhou Canc Hosp, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Oncol, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Lysimachia capillipes Capilliposide; non-small cell lung cancer; Gefitinib resistance; AKT;
D O I：
10.1016/j.jtho.2016.11.1791
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02b-123
引用
收藏
页码：S1268 / S1269
页数：2
相关论文
共 50 条
  • [1] Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance
    Zhang, Shi-rong
    Xu, Ya-si
    Jin, Er
    Zhu, Lu-cheng
    Xia, Bing
    Chen, Xu-feng
    Li, Fan-zhu
    Ma, Sheng-lin
    ACTA PHARMACOLOGICA SINICA, 2017, 38 (01) : 100 - 109
  • [2] Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance
    Shi-rong Zhang
    Ya-si Xu
    Er Jin
    Lu-cheng Zhu
    Bing Xia
    Xu-feng Chen
    Fan-zhu Li
    Sheng-lin Ma
    Acta Pharmacologica Sinica, 2017, 38 : 100 - 109
  • [3] Effect of sequential chemotherapy and gefitinib on survival outcome in advanced NSCLC with acquired gefitinib resistance.
    Wang Huijuan
    Zhang Mina
    Zhang Guo Wei
    Zhu Hui
    Wang Qiming
    Li Peng
    Yan Xiangtao
    Li Shaomei
    Ma Zhi Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Lysimachia Capillipes Capilliposide C Restores Radiation Sensitivity in Radiation Resistant Lung Cancer Cells by Enhancing ERRFI1 Expression
    Wu, K.
    Wang, B.
    Xu, Y.
    Feng, J.
    Zhu, L.
    Chen, X.
    Xia, B.
    Zhang, S.
    Chen, X.
    Ma, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S959 - S960
  • [5] ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
    Zhao, Hongbo
    Huang, Yutang
    Shi, Jingjing
    Dai, Yi
    Wu, Lanxiang
    Zhou, Honghao
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [6] Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib
    Xu, Ruitong
    Shen, Hua
    Guo, Renhua
    Sun, Jing
    Gao, Wen
    Shu, Yongqian
    BIOMEDICINE & PHARMACOTHERAPY, 2012, 66 (05) : 384 - 389
  • [7] FGFR1 Induces Acquired Resistance Against Gefitinib By Activating AKT/mTOR Pathway In NSCLC
    Zhang, Dan
    Han, Li-li
    Du, Fen
    Liu, Xiao-meng
    Li, Jin
    Wang, Hui-hui
    Song, Ming-hui
    Li, Zeng
    Li, Guo-yin
    ONCOTARGETS AND THERAPY, 2019, 12 : 9809 - 9816
  • [8] Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib.
    Pao, W.
    Balak, M. N.
    Riely, G. J.
    Li, A. R.
    Zakowski, M. F.
    Ladanyi, M.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 383S - 383S
  • [9] Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
    Terai, Hideki
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Nakayama, Sohei
    Hamamoto, Junko
    Arai, Daisuke
    Ishioka, Kota
    Ohgino, Keiko
    Ikemura, Shinnosuke
    Sato, Takashi
    Yoda, Satoshi
    Satomi, Ryosuke
    Naoki, Katsuhiko
    Betsuyaku, Tomoko
    MOLECULAR CANCER RESEARCH, 2013, 11 (07) : 759 - 767
  • [10] Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib
    Janjigian, Y. Y.
    Groen, H. J.
    Horn, L.
    Smit, E. F.
    Fu, Y.
    Wang, F.
    Shahidi, M.
    Denis, L. J.
    Pao, W.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345